Evidence of a drug-specific impact of experimentally selected paromomycin and miltefosine resistance on parasite fitness inLeishmania infantum | Zendy

Sarah Hendrickx | Zendy; Jolien Beyers | Zendy; Annelies Mondelaers | Zendy; Eline Eberhardt | Zendy; Laurence Lachaud | Zendy; Peter Delputte | Zendy; Paul Cos | Zendy; Louis Maes | Zendy

Open Access

Evidence of a drug-specific impact of experimentally selected paromomycin and miltefosine resistance on parasite fitness inLeishmania infantum

Author(s) -

Sarah Hendrickx,

Jolien Beyers,

Annelies Mondelaers,

Eline Eberhardt,

Laurence Lachaud,

Peter Delputte,

Paul Cos,

Louis Maes

Publication year - 2016

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkw096

Subject(s) - miltefosine , paromomycin , amastigote , biology , leishmaniasis , leishmania infantum , leishmania , drug resistance , pharmacology , microbiology and biotechnology , immunology , antibiotics , visceral leishmaniasis , parasite hosting , aminoglycoside , world wide web , computer science

Although miltefosine and paromomycin were only recently introduced to treat visceral leishmaniasis, increasing numbers of miltefosine treatment failures and occasional primary resistance to both drugs have been reported. Understanding alterations in parasite behaviour linked to drug resistance is essential to assess the propensity for emergence and spread of resistant strains, particularly since a positive effect on fitness has been reported for antimony-resistant parasites. This laboratory study compared the fitness of a drug-susceptible parent WT clinical Leishmania infantum isolate (MHOM/FR/96/LEM3323) and derived miltefosine and paromomycin drug-resistant lines that were experimentally selected at the intracellular amastigote level.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research